相关实验视频

Updated: May 3, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

在阿尔茨海默病小鼠模型中,AIBP控制TLR4炎症和线粒体功能障碍

Yi Sak Kim¹, Soo-Ho Choi¹, Keun-Young Kim²

¹Department of Medicine, University of California, San Diego, La Jolla, San Diego, CA, 92093, USA.

Journal of neuroinflammation

|September 28, 2024

概括

ApoA-I结合蛋白 (AIBP) 通过调节微质炎症反应和线粒体功能来保护阿尔茨海默病. 在小鼠模型中,AIBP的损失会加剧神经炎症,氧化应激和神经退行.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
细胞生物学细胞生物学

背景情况:

微质驱动的神经炎症在阿尔茨海默氏病 (AD) 发病过程中至关重要.
激活的微质细胞形成TLR4炎症平台,富含胆固醇的平台用于炎症信号传递.
ApoA-I结合蛋白 (AIBP) 与TLR4相互作用,准胆固醇减少的炎症性微质细胞.

研究的目的:

调查AIBP在调节TLR4炎症和阿尔茨海默病中微质功能中的作用.
在小鼠模型中确定AIBP缺乏对神经炎症,线粒体动态和AD进展的影响.

主要方法:

在体外研究中,使用暴露于粉样β (Aβ) 的微质细胞.
在体内研究使用具有和没有AIBP的APP/PS1转基因小鼠 (Apoa1bp-/- APP/PS1).
分析TLR4炎症支架的形成,线粒体形态,活性氧物种 (ROS),内质网膜扩张,Aβ斑块负载,神经元细胞死亡和动物生存.

主要成果:

Aβ诱导的TLR4炎症在微质细胞中形成.
Apoa1bp-/- APP/PS1微质表现出高分支线粒体,ROS增加和ER扩张.
与对照小鼠相比,Aβ斑块负担和神经元死亡增加,而Apoa1bp-/- APP/PS1小鼠的存活率下降.

结论:

AIBP调节微质中的TLR4炎症机和线粒体动力学.
在阿尔茨海默病中,AIBP对氧化压力和神经退行起着保护作用.
准AIBP可能为阿尔茨海默病提供治疗策略.

关键词:

一个AIBPP的AIBP.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在火焰中燃烧.脂质漂泊船是指脂质漂泊船,是指脂质漂泊船.微质细胞中的微质细胞线粒体中的线粒体.神经炎症是一种神经炎症.氧化应激是一种氧化应激.在 TLR4 中,

更多相关视频

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...